• Miltefosine Promotes Neutrophil Differentiation via Ras/MEK/

  2026-06-29

  The reference study reveals that Miltefosine, previously recognized for PI3K/Akt pathway inhibition, can activate the Ras/MEK/ERK cascade to restore neutrophil differentiation and bone marrow recovery in leukopenia models. This dual-pathway modulation highlights Miltefosine’s potential as a mechanistically distinct therapeutic agent for hematological disorders.

• GPNMB-Based Multimodal Model Predicts ESCC Immunotherapy Res

  2026-06-29

  This study develops and clinically validates a multimodal model integrating circulating GPNMB, tumor microenvironment signatures, and clinical-pathological data to predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). The mechanistic discovery of sGPNMB-driven CD8+ T cell exhaustion provides a new avenue for patient stratification and tailored immunotherapy.

• Tetrahydromagnolol: Optimizing Peripheral CB2 Receptor Agoni

  2026-06-28

  Tetrahydromagnolol stands out as a highly selective peripheral CB2 receptor agonist, enabling unparalleled precision in cannabinoid signaling and anti-inflammatory research. This guide delivers actionable protocols, troubleshooting tips, and strategic context for leveraging Tetrahydromagnolol in metastasis and GPCR-driven migration studies.

• EZH2 Modulation by Salidroside Protects Endothelial Cells fr

  2026-06-27

  The referenced study uncovers how salidroside (SAL) protects human endothelial cells from hydrogen peroxide-induced dysfunction by targeting the epigenetic regulator EZH2. By modulating key autophagy and inflammatory pathways, SAL demonstrates a mechanistic approach to mitigating endothelial dysfunction, advancing the understanding of vascular protection under oxidative stress.

• Ceftolozane/Tazobactam: Advances in β-Lactam Therapy for MDR

  2026-06-26

  The reference study introduces ceftolozane/tazobactam as a new cephalosporin/β-lactamase inhibitor combination with notable activity against resistant Gram-negative bacteria, especially Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. Its pharmacokinetic and pharmacodynamic advantages position it as a promising candidate for complicated intraabdominal and urinary tract infections, addressing gaps in current antibacterial strategies.

• Redefining Nrf2 Pathway Modulation: (S)-1-(3-fluoro-4-(trifl

  2026-06-26

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea enables advanced studies on the Nrf2 signaling pathway and osteoclast differentiation. This article delivers a mechanistic deep dive, unique protocol guidance, and strategic assay perspectives not found in prior literature.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-25

  Anlotinib hydrochloride from APExBIO unlocks advanced, reproducible anti-angiogenic workflows with superior selectivity for VEGFR2, PDGFRβ, and FGFR1. Backed by preclinical evidence, it empowers cancer research teams to achieve robust inhibition of endothelial cell migration and optimize tube formation assays with confidence.

• Reliable Workflows with 5-Aminolevulinic acid HCl (SKU B2070

  2026-06-25

  This in-depth guide addresses core laboratory challenges in heme biosynthesis, cell viability, and pathogen research by leveraging 5-Aminolevulinic acid HCl (SKU B2070). It integrates scenario-driven Q&As, protocol strategies, and data-backed comparisons to help biomedical researchers achieve reproducibility and quantitative accuracy using APExBIO’s high-purity reagent.

• VX-702: Applied Workflows for p38α MAPK Inhibition in Inflam

  2026-06-24

  VX-702, a highly selective p38α MAPK inhibitor, enables advanced inflammation and cardiovascular research through dual-action kinase inhibition and targeted dephosphorylation. Discover experimental workflows, troubleshooting strategies, and protocol optimizations that uniquely leverage VX-702’s structural and functional innovations.

• Caspase-3 Fluorometric Assay Kit: Bridging Apoptosis and Fer

  2026-06-23

  Explore the Caspase-3 Fluorometric Assay Kit and its role in unraveling the complex interplay between apoptosis and ferroptosis. This article uniquely analyzes how advanced caspase activity measurement empowers cross-talk studies, referencing cutting-edge research and practical assay guidance.

• PF-562271 HCl: Reliable FAK/Pyk2 Inhibition for Cancer Resea

  2026-06-23

  This article delivers a scenario-driven, evidence-based guide to using PF-562271 HCl (SKU A8345) in cancer research workflows, with practical insights for addressing common assay and data reproducibility challenges. By focusing on real laboratory scenarios—ranging from inhibitor selectivity to vendor reliability—it demonstrates how this selective FAK/Pyk2 inhibitor from APExBIO supports robust experimental outcomes and data confidence.

• BRD4 Inhibition Enhances Erastin-Induced Ferroptosis via ROS

  2026-06-22

  The referenced study demonstrates that BRD4 inhibitors, including I-BET-762, significantly potentiate erastin-induced ferroptosis across multiple cell lines by promoting reactive oxygen species (ROS) accumulation and downregulating FSP1. These findings clarify key mechanisms underlying the synergy between BET inhibition and ferroptosis induction in cancer models, offering new avenues for combinatorial therapeutic strategies.

• Chenodeoxycholic Acid (CDCA): Beyond Renal Protection—A Syst

  2026-06-22

  Explore the multifaceted research applications of Chenodeoxycholic Acid (CDCA) as an FXR agonist in cholesterol metabolism, nuclear receptor signaling, and integrated organ protection models. This article delivers unique systems-level insights for advanced metabolic and translational research.

• Mavorixafor Phase 3 Trial: Targeted CXCR4 Antagonism in WHIM

  2026-06-21

  The recent placebo-controlled phase 3 trial of mavorixafor demonstrates significant clinical benefit in WHIM syndrome by specifically antagonizing CXCR4 signaling. The study marks a pivotal advance in rare immunodeficiency therapeutics, setting a new benchmark for targeted, oral therapy and raising new directions for long-term management and research.

• Phosphatase Inhibitor Cocktail 2 (100X): Mechanism & Validat

  2026-06-20

  Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) provides robust, reproducible inhibition of diverse phosphatase classes, preserving protein phosphorylation in cell lysates and tissue extracts. Validated in biochemical assays, its spectrum includes tyrosine, acid, and alkaline phosphatases, making it essential for reliable signal transduction research.

436 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page